How do I… facilitate a rapid response to a public health emergency requiring plasma collection with a public–private partnership?

In March 2020, there were no treatment options for COVID‐19. Passive immune therapy including anti‐SARS‐CoV‐2 hyperimmune globulin (hIVIG) was a logical candidate for COVID‐19 therapeutic trials, given past success treating emerging pathogens with endogenous neutralizing antibodies. We established a...

Full description

Saved in:
Bibliographic Details
Published in:Transfusion (Philadelphia, Pa.) Pa.), 2021-10, Vol.61 (10), p.2814-2824
Main Authors: Miller, Maureen J., Skrzekut, Adam, Kracalik, Ian, Jones, Jefferson M., Lofy, Kathryn H., Konkle, Barbara A., Haley, N. Rebecca, Duvenhage, Michael, Bonnett, Tyler, Holbrook, Michael, Higgs, Elizabeth, Basavaraju, Sridhar V., Paranjape, Suman
Format: Article
Language:English
Subjects:
administration
Adult
Aged
Aged, 80 and over
Antibodies
blood center operations
Blood Specimen Collection
Clinical trials
Collaboration
COVID-19
COVID-19 - therapy
Data collection
Disease hot spots
donors
Emergencies
Emergency response
Epidemics
Female
Globulins
Humans
Immunization, Passive
Infections
Laboratories
Male
Middle Aged
Neutralization
Neutralizing
Plasma
Public Health
Public-Private Sector Partnerships
SARS-CoV-2
Severe acute respiratory syndrome
Severe acute respiratory syndrome coronavirus 2
Transfusion
Viral diseases
Viruses
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:In March 2020, there were no treatment options for COVID‐19. Passive immune therapy including anti‐SARS‐CoV‐2 hyperimmune globulin (hIVIG) was a logical candidate for COVID‐19 therapeutic trials, given past success treating emerging pathogens with endogenous neutralizing antibodies. We established a plasma collection protocol for persons recovered from COVID‐19. To speed recruitment in the first U.S. hotspot, Seattle, Washington, federal and state public health agencies collaborated with Bloodworks Northwest to collect convalescent plasma (CP) for manufacturing hIVIG. During March–December 2020, we identified and recruited prospective CP donors via letters to persons recovered from COVID‐19 with laboratory‐confirmed SARS‐CoV‐2 infection. Prospective donors were pre‐screened and administered a medical history survey. Anti‐SARS‐CoV‐2 neutralizing antibody (NAb) titers were classified as qualifying (≥1:80) or non‐qualifying (
ISSN:0041-1132
1537-2995
DOI:10.1111/trf.16630